Neovasc Inc. is no longer in violation of Nasdaq's listing requirements.
The specialty cardiovascular medical device company regained compliance after its stock price hovered above $1 for 10 consecutive days.
Neovasc regains Nasdaq listing compliance
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective